Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Erasca, Inc. (NASDAQ: ERAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage precision oncology issuer. Erasca files current reports on Form 8-K and other documents with the U.S. Securities and Exchange Commission (SEC) that describe financial results, corporate actions, and governance matters.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results for periods ended June 30 and September 30, 2025, where Erasca reported research and development expenses, general and administrative expenses, and net loss figures, along with commentary on its cash, cash equivalents, and marketable securities. Another Form 8-K details the results of the company’s annual meeting of stockholders, including the election of Class I directors and ratification of its independent registered public accounting firm.
For investors analyzing ERAS, these filings complement Erasca’s press releases about its RAS-targeting franchise, including ERAS-0015 and ERAS-4001. While the scientific and clinical details are often highlighted in news announcements, SEC filings provide the formal financial and corporate context, as well as risk factor discussions in periodic reports such as the Form 10-K that the company cites in its cautionary notes.
On Stock Titan, users can review Erasca’s SEC filings as they are made available through EDGAR and use AI-powered summaries to understand key points from lengthy documents, including earnings-related 8-Ks and proxy-related disclosures. This helps readers connect the company’s financial condition and governance decisions with its ongoing efforts to develop therapies for RAS/MAPK pathway-driven cancers.
Erasca, Inc. announced its financial results for the three months ended June 30, 2025 and furnished a press release containing the full results as Exhibit 99.1 to this Current Report. The filing notes the press release is being furnished rather than "filed," so it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings except by specific reference.
The Current Report identifies Exhibit 99.1 (press release) and a Cover Page Interactive Data File (104) as exhibits. No numerical financial data or consolidated financial statements are included in the text of this Form 8-K; readers are referred to the attached Exhibit 99.1 for the detailed results.
Erasca (Nasdaq: ERAS) filed a Form 8-K disclosing the 24 June 2025 annual meeting results. 241.8 million of 283.3 million entitled shares were represented (≈85%).
- Director elections: Jonathan Lim 196.99 M for / 2.19 M withheld; James Bristol 178.36 M for / 20.81 M withheld; Valerie Harding-Start 177.00 M for / 22.17 M withheld. All three Class I directors were elected for terms expiring in 2028.
- Auditor ratification: KPMG LLP received 240.25 M for, 1.27 M withheld, 0.31 M against; 0 broker non-votes.
No additional proposals were presented, and the filing notes no changes to governance, strategy, or capital structure.
Erasca, Inc. (ERAS) – Form 4 insider filing: Director Michael David Varney received a grant of 120,000 non-qualified stock options on 06/24/2025 at an exercise price of $1.45 per share. The options are subject to a one-year cliff; 100% vest on 06/24/2026, contingent on his continued service, and expire on 06/23/2035. No shares were purchased or sold; the transaction code “A” denotes an award. Following the grant, Varney beneficially owns 120,000 derivative securities, held directly. The filing does not list any other equity transactions or changes in common-stock ownership.
The option award aligns the director’s incentives with shareholder value creation, but also adds up to 120,000 potential new shares to the company’s fully diluted count once exercised.
SEC Form 4 snapshot for Erasca, Inc. (ERAS)
On June 26 2025, Director Jean I. Liu reported the receipt of a new equity award under Erasca’s incentive plan. The filing discloses 120,000 stock options (right to buy common shares) granted on June 24 2025 at an exercise price of $1.45 per share. All of the options vest in a single tranche on June 24 2026, provided Ms. Liu remains in continuous service, and they expire on June 23 2035.
- No non-derivative share transactions were reported; the disclosure relates solely to the derivative option grant.
- Following the grant, Ms. Liu shows beneficial ownership of 120,000 options, held directly.
- The transaction is coded “A” (grant without payment) and was executed outside a Rule 10b5-1 trading plan.
Option awards are routine director compensation meant to align governance incentives with shareholder value creation. The long-dated expiration (10 years) and one-year cliff vesting structure encourage strategic, long-term decision-making. The filing does not indicate any open-market buying or selling, nor does it alter Erasca’s capital structure. From an investment perspective, the event is informational rather than financially material, but it does confirm continued board engagement and standard equity-based retention practices.
Erasca, Inc. (ERAS) – Form 4 insider filing
Director Julie Hambleton received an option grant for 120,000 shares of common stock on 24 June 2025 at an exercise price of $1.45 per share. The option was issued at no cost, vests 100 % on 24 June 2026, and expires on 23 June 2035. Following the grant, Hambleton beneficially owns 120,000 derivative securities, held directly. No non-derivative share transactions were reported. The filing represents routine equity compensation for a board member and does not indicate immediate open-market buying or selling activity.
Key points from Erasca, Inc. (ERAS) Form 4
On 06/24/2025 the company granted Director Valerie Denise Harding a stock option for 120,000 common shares at an exercise price of $1.45. The transaction is coded “A” (acquisition) and is held directly by the director. According to the footnote, 100% of the option vests on 06/24/2026, provided the director remains in continuous service, and the option expires on 06/23/2035. After the grant the reporting person holds 120,000 derivative securities; no non-derivative share ownership or sales were reported.
No Rule 10b5-1 trading plan or other special conditions were indicated, and there were no accompanying purchases, sales, or exercises. The filing represents routine director compensation with limited immediate impact on Erasca’s capital structure or cash flow.
Form 4 overview: On 06/24/2025, Erasca, Inc. (ticker ERAS) granted Director Pratik S. Multani a stock option to purchase 120,000 shares of common stock at an exercise price of $1.45 per share.
Key terms:
- Vesting: 100% of the option vests on 06/24/2026, contingent on continued service.
- Expiration: 06/23/2035, providing a 10-year exercise window after vesting.
- Ownership form: Direct.
No other acquisitions, dispositions, or non-derivative holdings were reported. The filing reflects a routine equity incentive intended to align the director’s interests with shareholders rather than an open-market purchase or sale. The disclosure contains no financial performance data or forward-looking statements.
On June 26 2025, Director James Arthur Bristol submitted a Form 4 reporting an equity award from Erasca, Inc. (ERAS). The filing shows that on June 24 2025 he received 120,000 stock options with an exercise price of $1.45 per share. All of the options vest simultaneously on June 24 2026, provided he remains in continuous service, and they expire on June 23 2035. No open-market purchases or sales of common stock were disclosed, leaving Bristol’s post-transaction direct derivative holdings at 120,000 options.
The transaction constitutes an incentive grant only; it does not alter the current share float, generate cash proceeds, or affect near-term earnings. Nevertheless, the award ties the director’s future value creation to long-term share-price performance.
On 06/24/2025, Erasca, Inc. (ERAS) director Alexander W. Casdin was granted 120,000 stock options to purchase common shares at an exercise price of $1.45. The award was disclosed in a Form 4 filed on 06/26/2025 and is classified as an acquisition rather than an open-market buy.
The options vest 100% on 06/24/2026, contingent on continued board service, and will expire on 06/23/2035. Casdin now holds 120,000 derivative securities, all directly owned. Because no underlying shares were bought or sold and the grant carries no immediate cash outlay, the filing reflects routine director compensation designed to align long-term incentives rather than a directional view on near-term share price.